Ironwood Pharmaceuticals reported first-quarter earnings of $0.24 per share, beating analyst forecasts of $0.07 by $0.17 and marking its first profitable quarter since the prior year.

Total revenue for the quarter surpassed consensus projections, reflecting solid uptake of the company’s marketed therapies across its gastrointestinal portfolio.

The company reversed a $0.14 per share loss from Q1 last year, driven by improved cost controls and increased sales volume in its core product lineup.